On Tuesday, News Corp (NASDAQ:NWSA)’s shares declined -2.29% to $15.35.
News Corp (NWSA) partner Move, Inc., stepped out emphatically with the introduction of a new graphic identity and national advertising campaign that position the brand as the best – and truest – provider of real estate information and services for buyers, sellers and renters of properties in the U.S.
The new work was previewed here this afternoon by Move CEO Ryan O’Hara in keynote remarks to more than 2,000 industry leaders and real estate professionals gathered for the 2015 Realtors® Legislative Meetings & Trade Expo.
The campaign represents the biggest and boldest marketing initiative in realtor.com®’s nearly 20-year history and unfolds against the backdrop of a marketplace that has been seismically altered by the recent acquisition of Move by News Corp and the merger of competitors Zillow and Trulia. At stake are online home listings and homes-for-sale ads surpassing $9 billion annually, according to a recent research report by Goldman, Sachs & Co. The campaign also coincides with the continued surge of realtor.com®’s business, which has seen record growth in web and mobile visitors and the brand’s recent ascension to the industry’s #2 position.
News Corporation, a media and information services company, focuses on creating and distributing authoritative and engaging content to consumers and businesses worldwide. The company operates through News and Information Services, Cable Network Programming, Digital Real Estate Services, Book Publishing, and Digital Education segments.
CTI BioPharma Corp (NASDAQ:CTIC)’s shares dropped -2.22% to $1.76.
CTI BioPharma Corp (CTIC) stated financial results for the first quarter ended March 31, 2015.
First Quarter 2015 Financial Results
Total revenues for the quarter ended March 31, 2015 were $2.7 million contrast to $1.4 million for the same period in 2014, which comprises PIXUVRI net product revenues of $0.8 million and license contract revenues of $1.9 million for the quarter ended March 31, 2015 contrast to $1.3 million and $0.1 million, respectively, for the same period in 2014.
Net loss for the quarter ended March 31, 2015 was $28.6 million, or $0.16 per share, contrast to a net loss of $29.0 million, or $0.20 per share, for the same period in 2014.
For the quarter ended March 31, 2015, cash and cash equivalents totaled $44.4 million.
2015 Financial Outlook
CTI BioPharma reaffirms preceding financial guidance that it anticipates total revenues for 2015 will be about $50 million to $55 million, and it anticipates that non-GAAP operating loss for 2015 will be about $75 million to $85 million, which excludes non-cash share-based compensation expense. These financial projections are primarily based on factors formerly outlined in the Company’s fourth quarter and full year 2014 financial results press release.
CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union.
At the end of Tuesday’s trade, Canadian Pacific Railway Limited (USA) (NYSE:CP)‘s shares dipped -2.19% to $182.71.
Canadian Pacific Railway Limited (USA) (CP) declared that Mark Erceg has been designated Executive Vice-President and Chief Financial Officer effective May 18, 2015.
Erceg joins CP from Masonite International Corp. where he had been Executive Vice-President and Chief Financial Officer since 2010. Erceg brings to CP over 20 years of financial administration experience.
Canadian Pacific Railway Limited, through its auxiliaries, operates a transcontinental railway in Canada and the United States. The company provides logistics and supply chain expertise services. It transports bulk commodities, counting grain, coal, fertilizers, and sulphur; and intermodal traffic comprising retail goods in overseas containers that can be transported by train, ship, and truck, in addition to in domestic containers and trailers that can be moved by train and truck.
Arbor Realty Trust Inc (NYSE:ABR), ended its Tuesday’s trading session with -2.18% loss, and closed at $6.74.
Arbor Realty Trust Inc (ABR) declared financial results for the first quarter ended March 31, 2015. Arbor stated net income for the quarter of $15.0 million, or $0.30 per diluted common share, contrast to $5.9 million, or $0.12 per diluted common share for the quarter ended March 31, 2014. Adjusted funds from operations (“AFFO”) for the quarter was $18.2 million, or $0.36 per diluted common share, contrast to $7.9 million, or $0.16 per diluted common share for the quarter ended March 31, 2014.1
Portfolio Activity
Loan and investment portfolio activity during the first quarter of 2015 compriseed of:
- 14 new loan originations totaling $209.9 million, of which 12 were bridge loans for $193.9 million.
- One defaulted first mortgage note acquisition for $116.0 million.
- Payoffs and pay downs on 15 loans totaling $173.9 million.
At March 31, 2015, the loan and investment portfolio’s unpaid principal balance, not taking into account loan loss reserves, was about $1.75 billion, with a weighted average current interest pay rate of 5.47%, contrast to $1.60 billion and 5.44% at December 31, 2014. Counting certain fees earned and costs associated with the loan and investment portfolio, the weighted average current interest pay rate was 6.07% at March 31, 2015, contrast to 6.16% at December 31, 2014.
Arbor Realty Trust, Inc., a specialized real estate finance company, invests in various structured finance investments. The company invests in multifamily and commercial real estate-related bridge and mezzanine loans, counting junior participating interests in first mortgages, preferred and direct equity, and discounted mortgage notes and other real estate-related assets.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
